Danosumab is developed by Post Graduate Institute of Medical Education and Research, Chandigarh.

What development phase is Danosumab in?

Danosumab is FDA-approved (marketed).

Last reviewed 2026-04-19 · How we verify

Danosumab

Post Graduate Institute of Medical Education and Research, Chandigarh · FDA-approved active Small molecule

At a glance

Generic name	Danosumab
Also known as	Drug Arm
Sponsor	Post Graduate Institute of Medical Education and Research, Chandigarh
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

RANKL Antibody for Acute Charcot Neuro-osteoarthropathy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Danosumab CI brief — competitive landscape report
Danosumab updates RSS · CI watch RSS
Post Graduate Institute of Medical Education and Research, Chandigarh portfolio CI